CN106266969A - 羚羊安宫胶囊及其制备方法和应用 - Google Patents
羚羊安宫胶囊及其制备方法和应用 Download PDFInfo
- Publication number
- CN106266969A CN106266969A CN201610795369.5A CN201610795369A CN106266969A CN 106266969 A CN106266969 A CN 106266969A CN 201610795369 A CN201610795369 A CN 201610795369A CN 106266969 A CN106266969 A CN 106266969A
- Authority
- CN
- China
- Prior art keywords
- parts
- saigae tataricae
- capsule
- radix
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 56
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 41
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 27
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims abstract description 27
- 229940079593 drug Drugs 0.000 claims abstract description 26
- 241000255791 Bombyx Species 0.000 claims abstract description 20
- 201000009240 nasopharyngitis Diseases 0.000 claims abstract description 7
- 239000000843 powder Substances 0.000 claims description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000013543 active substance Substances 0.000 claims description 14
- 239000012567 medical material Substances 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 9
- 238000009835 boiling Methods 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 229940124579 cold medicine Drugs 0.000 claims description 2
- 238000007796 conventional method Methods 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 208000024891 symptom Diseases 0.000 abstract description 13
- 238000010438 heat treatment Methods 0.000 abstract description 9
- 208000011580 syndromic disease Diseases 0.000 abstract description 6
- 231100000614 poison Toxicity 0.000 abstract description 4
- 239000003440 toxic substance Substances 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 3
- 230000002936 tranquilizing effect Effects 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 206010011224 Cough Diseases 0.000 description 6
- 206010037660 Pyrexia Diseases 0.000 description 6
- 230000036760 body temperature Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000000392 somatic effect Effects 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010063659 Aversion Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 235000014676 Phragmites communis Nutrition 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000010753 nasal discharge Diseases 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- -1 polysorbate60-80 Chemical compound 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 240000007509 Phytolacca dioica Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 235000018992 Prunus glandulosa Nutrition 0.000 description 1
- 240000001619 Prunus glandulosa Species 0.000 description 1
- 235000013999 Prunus japonica Nutrition 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/413—Gall bladder; Bile
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Zoology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Insects & Arthropods (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于医药技术领域,具体涉及一种羚羊安宫胶囊及其制备方法和应用。所述羚羊安宫胶囊,由如下重量份配比的原料药制成:人工牛黄15‑25份、羚羊角15‑25份、桂枝10‑20份、蝉蜕10‑20份、姜黄10‑20份、黄芩10‑20份、炒僵蚕10‑20份、大黄5‑15份、黄连5‑15份、栀子10‑20份、石膏10‑20份、川贝母10‑20份、郁金10‑20份、冰片10‑20份。诸药配伍,共奏清热解毒,表里双解,镇心安神之功效,使表热得解,里热得清,发热自止。羚羊安宫胶囊临床用于所致的小儿感冒发热,有较强的降温效果,并能缓解临床症状体征,有效率高,且安全可靠。
Description
技术领域
本发明属于医药技术领域,具体涉及一种羚羊安宫胶囊及其制备方法和应用。
背景技术
小儿感冒发热是儿科最常见的疾病,5岁以下儿童平均每年罹患感冒4-5次,相当于现代医学的“急性上呼吸道感染”,包括鼻咽炎、咽炎、扁桃体炎等。本病约以上由病毒感染所致,机体免疫力下降时可合并细菌感染。由于可选择的西药抗病毒药有限及副作用大,加之目前病原学检查多滞后于临床。故中医治疗感冒发热以疗效好、副作用少的优势得到业界人士以及患儿家长的普遍认同。但是,常规的感冒药,尤其是感冒引起的发热,常规的抗感冒药和退烧药的效果不够好。表现为停药后继续发热。
本发明人总结以往工作经验,认为感冒发热病机为外感风热或风寒入里化热而导致的表里同热证。症见发热恶寒,头身疼痛,咳嗽,小便黄赤,大便秘结等。因此,需调整处方,提供一种表里双解的清热解毒药物,从而彻底治愈小儿感冒和感冒引起的发热。
发明内容
为了解决上述的技术问题,本发明提供了一种羚羊安宫胶囊及其制备方法。
一种羚羊安宫胶囊,由如下重量份配比的原料药制成:
人工牛黄15-25份、羚羊角15-25份、桂枝10-20份、蝉蜕10-20份、姜黄10-20份、黄芩10-20份、炒僵蚕10-20份、大黄5-15份、黄连5-15份、栀子10-20份、石膏10-20份、川贝母10-20份、郁金10-20份、冰片10-20份。
优选的,上述的羚羊安宫胶囊,由如下重量份配比的原料药制成:
人工牛黄18-22份、羚羊角18-22份、桂枝13-17份、蝉蜕13-17份、姜黄13-17份、黄芩13-17份、炒僵蚕13-17份、大黄8-12份、黄连8-12份、栀子13-17份、石膏13-17份、川贝母13-17份、郁金13-17份、冰片13-17份。
更优选的,上述的羚羊安宫胶囊,由如下重量份配比的原料药制成:
人工牛黄20份、羚羊角20份、桂枝15份、蝉蜕15份、姜黄15份、黄芩15份、炒僵蚕15份、大黄10份、黄连10份、栀子15份、石膏15份、川贝母15份、郁金15份、冰片15份。
本发明的以上组成中,各味中药的重量是以生药计算的,如果以克为单位,如制成制剂,则因制剂的大小不同可制成100-1000剂。所述100-1000剂是指单位剂量的制剂形式,如片剂100-1000片,胶囊剂100-1000粒,颗粒剂100-1000g,口服液100-1000ml,膏剂100-1000g,丸剂100-1000丸等。
以上组成是按重量作为配比的,在生产时可按照相应比例增大或减少,如大规模牛产可以以kg为单位,或以t(吨)为单位;小规模制剂也可以以g为单位。重量可以增大或者减小,但各组成之间的生药材重量配比的比例不变。
以上重量配比的比例是经过科学筛选得到的,对于特殊病人,如重症或轻症,肥胖或瘦小的病人,可以相应调整组成的量的配比,增加或减少不超过100%,药效基本不变。
本发明的羚羊安宫胶囊,可单独或根据需要可以加入一些药物可接受的辅料,可以采用制剂学常规技术制备该药物制剂。在制成药物制剂时可以制成任何可药用的口服剂型,这些剂型选自:颗粒剂、片剂、胶囊剂、口服液、口含剂、丸剂、散剂,优选为胶囊剂。
上述的羚羊安宫胶囊的制备方法,包含如下步骤:
(1)羚羊角、冰片、人工牛黄分别粉碎成细粉,备用;
(2)取石膏加8倍水量,煎煮1小时后,煎煮液备用;桂枝、蝉蜕、姜黄、黄芩、炒僵蚕、大黄、黄连、栀子、川贝母、郁金十味药材,加水煎煮三次,加水量依次为药材重量的8、8、6倍量,煎煮时间依次为3、2、1小时,合并三次煎液及石膏煎煮液,滤过,滤液60℃浓缩至相对密度为1.2-1.3的稠膏,干燥,粉碎成细粉;
(3)步骤(2)制得的药物细粉与步骤(1)制得的羚羊角细粉、冰片细粉、人工牛黄细粉混合使均匀,即得本发明羚羊安宫胶囊的活性物质;
(4)该活性物质单独或与药物可接受的辅料混合,按照制剂学常规方法制得。
所述的药物可接受的辅料选自:淀粉、硬脂酸镁、甘露醇、山梨醇、山梨酸或钾盐、焦亚硫酸钠、亚硫酸氢钠、硫代硫酸钠、盐酸半胱氨酸、巯基乙酸、蛋氨酸、维生素A、维生素C、维生素E、维生素D、氮酮、EDTA二钠、EDTA钙钠,一价碱金属的碳酸盐、醋酸盐、磷酸盐或其水溶液、盐酸、醋酸、硫酸、磷酸、氨基酸、氯化钠、氯化钾、乳酸钠、木糖醇、右旋糖苷、甘氨酸、乳糖、甘露糖醇、硅衍生物、纤维素及其衍生物、藻酸盐、明胶、聚乙烯吡咯烷酮、甘油、丙二醇、乙醇、吐温60-80、司班-80、蜂蜡、羊毛脂、液体石蜡、十六醇、没食子酸酯类、三乙醇胺、碱性氨基酸、尿素、尿囊素、碳酸钙、碳酸氢钙、表面活性剂、聚乙二醇、环糊精、β-环糊精、磷脂类材料、高岭土、滑石粉、硬脂酸钙等。
上述的羚羊安宫胶囊在制备治疗小儿感冒药物中的应用。
本发明的羚羊安宫胶囊的用法用量:口服。10岁以上一次1粒,一日3次;4-9岁儿童一次1/2粒,一日3次:4岁以下儿童遵医嘱服用。
高热为小儿疾病过程中常见症状之一,多因外感风寒化热,或外感风热所致,故本发明的羚羊安宫胶囊处方中,用柴胡解表疏肝,牛黄清热解毒,镇惊安神,豁痰开窍共为君药;臣以羚羊角透热平肝,桂枝解肌发表,蝉蜕、姜黄、黄芩解表清热,僵蚕、大黄、黄连、梔子、石膏清泄里热,川贝母、郁金化痰止咳,冰片透表、清心安神共为佐使药,诸药配伍,共奏清热解毒,表里双解,镇心安神之功效,使表热得解,里热得清,发热自止。适用于外感风热或风寒入里化热而导致的表里同热证症见发热恶寒,头身疼痛,咳嗽,小便黄赤,大便秘结等。
羚羊安宫胶囊临床用于所致的小儿感冒发热,有较强的降温效果,并能缓解临床症状体征,有效率高,且安全可靠。
具体实施方式
下面结合具体实施例对本发明作更进一步的说明,以便本领域的技术人员更了解本发明,但并不因此限制本发明。
实施例1
一种羚羊安宫胶囊,由如下重量配比的原料药制成:
人工牛黄20g、羚羊角20g、桂枝15g、蝉蜕15g、姜黄15g、黄芩15g、炒僵蚕15g、大黄10g、黄连10g、栀子15g、石膏15g、川贝母15g、郁金15g、冰片15g。
该羚羊安宫胶囊的制备方法:
(1)羚羊角、冰片、人工牛黄分别粉碎成细粉,备用;
(2)取石膏加8倍水量,煎煮1小时后,煎煮液备用;桂枝、蝉蜕、姜黄、黄芩、炒僵蚕、大黄、黄连、栀子、川贝母、郁金十味药材,加水煎煮三次,加水量依次为药材重量的8、8、6倍量,煎煮时间依次为3、2、1小时,合并三次煎液及石膏煎煮液,滤过,滤液60℃浓缩至相对密度为1.2-1.3的稠膏,干燥,粉碎成细粉;
(3)步骤(2)制得的药物细粉与步骤(1)制得的羚羊角细粉、冰片细粉、人工牛黄细粉混合使均匀,即得本发明羚羊安宫胶囊的活性物质;
(4)该活性物质灭菌,在三十万级洁净区内分装胶囊,分装瓶即可。共制得胶囊420粒。
实施例2
一种羚羊安宫胶囊,由如下重量配比的原料药制成:
人工牛黄18g、羚羊角22g、桂枝13g、蝉蜕17g、姜黄13g、黄芩17g、炒僵蚕13g、大黄12g、黄连8g、栀子17g、石膏13g、川贝母17g、郁金13g、冰片17g。
该羚羊安宫胶囊的制备方法:
(1)羚羊角、冰片、人工牛黄分别粉碎成细粉,备用;
(2)取石膏加8倍水量,煎煮1小时后,煎煮液备用;桂枝、蝉蜕、姜黄、黄芩、炒僵蚕、大黄、黄连、栀子、川贝母、郁金十味药材,加水煎煮三次,加水量依次为药材重量的8、8、6倍量,煎煮时间依次为3、2、1小时,合并三次煎液及石膏煎煮液,滤过,滤液60℃浓缩至相对密度为1.2-1.3的稠膏,干燥,粉碎成细粉;
(3)步骤(2)制得的药物细粉与步骤(1)制得的羚羊角细粉、冰片细粉、人工牛黄细粉混合使均匀,即得本发明羚羊安宫胶囊的活性物质;
(4)该活性物质灭菌,在三十万级洁净区内分装胶囊,分装瓶即可。共制备胶囊420粒。
实施例3
一种羚羊安宫胶囊,由如下重量配比的原料药制成:
人工牛黄22g、羚羊角18g、桂枝17g、蝉蜕13g、姜黄17g、黄芩13g、炒僵蚕17g、大黄8g、黄连12g、栀子13g、石膏17g、川贝母13g、郁金17g、冰片13g。
该羚羊安宫胶囊的制备方法:
(1)羚羊角、冰片、人工牛黄分别粉碎成细粉,备用;
(2)取石膏加8倍水量,煎煮1小时后,煎煮液备用;桂枝、蝉蜕、姜黄、黄芩、炒僵蚕、大黄、黄连、栀子、川贝母、郁金十味药材,加水煎煮三次,加水量依次为药材重量的8、8、6倍量,煎煮时间依次为3、2、1小时,合并三次煎液及石膏煎煮液,滤过,滤液60℃浓缩至相对密度为1.2-1.3的稠膏,干燥,粉碎成细粉;
(3)步骤(2)制得的药物细粉与步骤(1)制得的羚羊角细粉、冰片细粉、人工牛黄细粉混合使均匀,即得本发明羚羊安宫胶囊的活性物质;
(4)该活性物质灭菌,在三十万级洁净区内分装胶囊,分装瓶即可。共制备胶囊420粒。
实施例4
一种羚羊安宫胶囊,由如下重量配比的原料药制成:
人工牛黄15g、羚羊角25g、桂枝10g、蝉蜕20g、姜黄10g、黄芩20g、炒僵蚕10g、大黄15g、黄连5g、栀子20g、石膏10g、川贝母20g、郁金10g、冰片20g。
该羚羊安宫胶囊的制备方法:
(1)羚羊角、冰片、人工牛黄分别粉碎成细粉,备用;
(2)取石膏加8倍水量,煎煮1小时后,煎煮液备用;桂枝、蝉蜕、姜黄、黄芩、炒僵蚕、大黄、黄连、栀子、川贝母、郁金十味药材,加水煎煮三次,加水量依次为药材重量的8、8、6倍量,煎煮时间依次为3、2、1小时,合并三次煎液及石膏煎煮液,滤过,滤液60℃浓缩至相对密度为1.2-1.3的稠膏,干燥,粉碎成细粉;
(3)步骤(2)制得的药物细粉与步骤(1)制得的羚羊角细粉、冰片细粉、人工牛黄细粉混合使均匀,即得本发明羚羊安宫胶囊的活性物质;
(4)该活性物质灭菌,在三十万级洁净区内分装胶囊,分装瓶即可。共制备胶囊420粒。
实施例5
一种羚羊安宫胶囊,由如下重量配比的原料药制成:
人工牛黄25g、羚羊角15g、桂枝20g、蝉蜕10g、姜黄20g、黄芩10g、炒僵蚕20g、大黄5g、黄连15g、栀子10g、石膏20g、川贝母10g、郁金20g、冰片10g。
该羚羊安宫胶囊的制备方法:
(1)羚羊角、冰片、人工牛黄分别粉碎成细粉,备用;
(2)取石膏加8倍水量,煎煮1小时后,煎煮液备用;桂枝、蝉蜕、姜黄、黄芩、炒僵蚕、大黄、黄连、栀子、川贝母、郁金十味药材,加水煎煮三次,加水量依次为药材重量的8、8、6倍量,煎煮时间依次为3、2、1小时,合并三次煎液及石膏煎煮液,滤过,滤液60℃浓缩至相对密度为1.2-1.3的稠膏,干燥,粉碎成细粉;
(3)步骤(2)制得的药物细粉与步骤(1)制得的羚羊角细粉、冰片细粉、人工牛黄细粉混合使均匀,即得本发明羚羊安宫胶囊的活性物质;
(4)该活性物质灭菌,在三十万级洁净区内分装胶囊,分装瓶即可。共制备胶囊420粒。
对实施例1制备的羚羊安宫胶囊进行了临床试验,详情如下:
1.资料与方法
1.1一般资料
选取确诊为感冒发热患儿120例,随机分为对照组和观察组。对照组60例患者,男性37例,女性23例,年龄2~8岁,平均年龄(4.24±2.22)岁,病程为1d至6d,平均病程为(3.47±1.25)d。观察组60例患者,男性34例,女性26例,年龄2~7岁,平均年龄(4.58±2.26)岁,病程为1d至7d,平均病程为(3.41±1.24)d。两组患者年龄、性别、病程等基本资料比较无统计学意义(P>0.05),具有可比性。
1.1.2诊断标准:
西医诊断标准:参照第7版《诸福棠实用儿科学》中急性上呼吸道感染诊断标准制定。①全身症状:发热,伴见恶寒、头痛、四肢及腰背肌肉酸痛。②局部症状:流涕、打喷嚏、鼻塞、咽痛、声嘶、时有咳嗽等。
中医诊断标准:按国家中医药管理局《中医病症诊断疗效标准》中感冒制定。表里同热证,症见发热恶寒,头身疼痛,咳嗽,小便黄赤,大便秘结等。
1.1.3纳入病例标准
①符合西医诊断标准及中医诊断标准;
②年龄范围为1-14岁儿童;
③病程≤7天者;
④同意配合完成本项研究,并签署知情同意书。
1.1.4排除病例标准
①排除重度营养不良者,对本药过敏者,或伴心血管、肝、肾和造血系统等严重全身性疾病患儿;
②下呼吸道感染患儿;
③未按规定用药者,无法判断疗效或资料不全影响疗效判定者;
1.2方法
1.2.1治疗方法
观察组给予本发明的羚羊安宫胶囊,10岁以上一次1粒,一日3次;4-9岁儿童一次1/2粒,一日3次:4岁以下儿童遵医嘱服用。
对照组予以小儿柴桂退热颗粒袋(贵州百灵企业集团制药股份有限公司,批号:国药准字:Z20050429)。服用方法:开水冲服,1岁,每次1/3袋,1-3岁,每次1/2袋;4-7岁,每次1袋;8-14岁,每次1.5袋;一日3次,2天为一个疗程。该药功用主治与试验用药相近,是目前国内疗效较为肯定的法定同类药物,符合公认有效、安全、可比原则。
2d为一疗程。
1.2.2观察指标
1)疗效观测:
①主要症状:发热。
②次要症状:恶寒、鼻塞、流涕、喷嚏、咳嗽、咳痰。
③相关体征:体温、咽红情况、扁桃体情况、舌象。
④体温变化:及时记录治疗前及每次服药后体温,重点记录药物起效时间、体温降至正常时间及体温复升情况。以体温下降≥0.5℃为起效标准。
症状体征评分以无、轻、中、重分别评为0、1、2、3分。
2)安全性指标:三大常规、肝肾功及心电图。
1.2.3疗效判定标准
疗效判定根据中华人民共和国卫生部发布的《中药新药临床研究指导原则》。
①痊愈:服药24~48h内体温恢复正常不再回升,临床症状、体征积分值减少≥95%。
②显效:服药24~48h内体温恢复正常,临床症状、体征积分值减少≥70%。
③有效:服药24~48h内体温恢复正常,临床症状、体征积分值减少≥30%。
④无效:未达到以上标准者,积分值减少不足30%。
1.2.4统计学处理
采用SPSS16.0软件对数据进行统计学处理,计数资料采用卡方检验,以P<0.05为有显著差异性,提示有统计学意义。
2.结果
2.1两组临床疗效比较
治疗前两组的症状体征积分比较差异无统计学意义(P>0.05),具有可比性。治疗后两组的症状体征积分均较治疗前明显降低,差异具有统计学意义(P<0.05);观察组降低程度明显优于对照组,差异具有统计学意义(P<0.05);观察组临床愈显率和总有效率均明显高于对照组,差异具有统计学意义(P<0.05),见表1、2.
表1 两组治疗前后症状体征积分比较
注:*表示与治疗前比较P<0.05;#表示与对照组治疗后比较P<0.05。
表2 两组临床疗效比较(例)
组别 | n | 治愈 | 显效 | 有效 | 无效 | 愈显率(%) | 总有效率(%) |
观察组 | 60 | 32 | 20 | 7 | 1 | 86.67* | 98.33** |
对照组 | 60 | 16 | 21 | 8 | 15 | 61.67 | 75.00 |
注:*表示与对照组比较,P<0.05。
2.2两组治疗体温变化比较
观察组在起效时间、体温降至正常时间及体温复升情况方面均明显优于对照组,差异具有统计学意义(P<0.05),见表3
表3 两组治疗体温变化比较
2.3安全性观察
治疗后未见三大常规、肝肾功及心电图有明显变化。
Claims (7)
1.一种羚羊安宫胶囊,由如下重量份配比的原料药制成:
人工牛黄15-25份、羚羊角15-25份、桂枝10-20份、蝉蜕10-20份、姜黄10-20份、黄芩10-20份、炒僵蚕10-20份、大黄5-15份、黄连5-15份、栀子10-20份、石膏10-20份、川贝母10-20份、郁金10-20份、冰片10-20份。
2.根据权利要求1所述的羚羊安宫胶囊,其特征在于,由如下重量份配比的原料药制成:
人工牛黄18-22份、羚羊角18-22份、桂枝13-17份、蝉蜕13-17份、姜黄13-17份、黄芩13-17份、炒僵蚕13-17份、大黄8-12份、黄连8-12份、栀子13-17份、石膏13-17份、川贝母13-17份、郁金13-17份、冰片13-17份。
3.根据权利要求2所述的羚羊安宫胶囊,其特征在于,由如下重量份配比的原料药制成:
人工牛黄20份、羚羊角20份、桂枝15份、蝉蜕15份、姜黄15份、黄芩15份、炒僵蚕15份、大黄10份、黄连10份、栀子15份、石膏15份、川贝母15份、郁金15份、冰片15份。
4.根据权利要求1或2或3所述的羚羊安宫胶囊,其特征在于,其剂型形式为口服制剂。
5.根据权利要求4所述的羚羊安宫胶囊,其特征在于,其剂型形式为胶囊剂。
6.权利要求1或2或3所述的羚羊安宫胶囊的制备方法,包含如下步骤:
(1)羚羊角、冰片、人工牛黄分别粉碎成细粉,备用;
(2)取石膏加8倍水量,煎煮1小时后,煎煮液备用;桂枝、蝉蜕、姜黄、黄芩、炒僵蚕、大黄、黄连、栀子、川贝母、郁金十味药材,加水煎煮三次,加水量依次为药材重量的8、8、6倍量,煎煮时间依次为3、2、1小时,合并三次煎液及石膏煎煮液,滤过,滤液60℃浓缩至相对密度为1.2-1.3的稠膏,干燥,粉碎成细粉;
(3)步骤(2)制得的药物细粉与步骤(1)制得的羚羊角细粉、冰片细粉、人工牛黄细粉混合使均匀,即得本发明羚羊安宫胶囊的活性物质;
(4)该活性物质单独或与药物可接受的辅料混合,按照制剂学常规方法制得。
7.权利要求1或2或3所述的羚羊安宫胶囊在制备治疗小儿感冒药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610795369.5A CN106266969A (zh) | 2016-08-31 | 2016-08-31 | 羚羊安宫胶囊及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610795369.5A CN106266969A (zh) | 2016-08-31 | 2016-08-31 | 羚羊安宫胶囊及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106266969A true CN106266969A (zh) | 2017-01-04 |
Family
ID=57672533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610795369.5A Pending CN106266969A (zh) | 2016-08-31 | 2016-08-31 | 羚羊安宫胶囊及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106266969A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101269204A (zh) * | 2008-04-24 | 2008-09-24 | 张晴龙 | 一种安宫牛黄滴丸及其制备方法 |
CN101766787A (zh) * | 2009-12-21 | 2010-07-07 | 武月萍 | 治疗高热、咳喘的灌肠液 |
-
2016
- 2016-08-31 CN CN201610795369.5A patent/CN106266969A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101269204A (zh) * | 2008-04-24 | 2008-09-24 | 张晴龙 | 一种安宫牛黄滴丸及其制备方法 |
CN101766787A (zh) * | 2009-12-21 | 2010-07-07 | 武月萍 | 治疗高热、咳喘的灌肠液 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106138360A (zh) | 一种中药组合物及其制备方法、应用 | |
CN102319294B (zh) | 双香草制剂及其制备方法 | |
CN105055606A (zh) | 一种治疗感冒的药物 | |
CN102727787B (zh) | 一种快速降低转氨酶与保肝的药物 | |
CN102139051B (zh) | 清热解毒软胶囊在制备用于治疗病毒性肺炎药物中的应用 | |
CN102793876B (zh) | 一种治疗不明原因发热的药物组合物及其制备方法和用途 | |
CN106266969A (zh) | 羚羊安宫胶囊及其制备方法和应用 | |
CN105616581A (zh) | 一种含有格列吡嗪的治疗糖尿病的药物组合物及其制备方法 | |
CN113288992A (zh) | 一种用于预防和/或治疗新型冠状病毒引发的疾病的中药组合物、其制备方法及用途 | |
CN116036199B (zh) | 中药组合物在制备辅助治疗儿童慢性咳嗽的药物中的应用 | |
CN104800675A (zh) | 用于治疗活动期溃疡性结肠炎的药物 | |
CN104825624A (zh) | 一种中药组合物在制备治疗疱疹性口腔炎的药物中的应用 | |
CN104491637B (zh) | 一种治疗感冒后咳嗽的复方组合药物及其制备方法与应用 | |
CN107320709A (zh) | 一种治疗小儿哮喘的中药组合物 | |
CN102973856B (zh) | 一种抗感冒的药物组合物及其制备方法 | |
CN102416147B (zh) | 一种治疗戒毒人员的躁狂症的药物组合物 | |
CN106215080A (zh) | 一种含有盐酸丙卡特罗的治疗小儿支气管哮喘的药物组合物及其制备方法 | |
CN107095977A (zh) | 一种具有祛火排毒功效的药剂及其药物配方和制备方法 | |
CN106215124A (zh) | 平肝胶囊及其制备方法和应用 | |
CN105687499A (zh) | 一种含有倍他洛尔的治疗高血压的药物组合物及其制备方法 | |
CN104958530A (zh) | 一种治疗小儿肺炎的中药组合物 | |
CN106362087A (zh) | 金羚胶囊及其制备方法和应用 | |
CN105796952A (zh) | 一种含有格列喹酮的治疗糖尿病的药物组合物及其制备方法 | |
CN106267082A (zh) | 养肝止痛胶囊及其制备方法和应用 | |
CN104758346A (zh) | 一种治疗偏头痛的药物及其制备方法、制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
DD01 | Delivery of document by public notice |
Addressee: Tang Jie Document name: Notification of Passing Examination on Formalities |
|
DD01 | Delivery of document by public notice | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170104 |
|
RJ01 | Rejection of invention patent application after publication |